Observational studyTranslational stroke research2026
Intracranial Mitochondrial Microparticles Promote Cerebral Edema via Endothelial Injury in Stroke.
Observational study in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04637074 (Registrated Cohort Study on Thrombectomy for Stroke), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Registrated Cohort Study on Thrombectomy for Stroke
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Vascular endothelial injury underlies the development of severe complications following acute ischemic stroke. While mitochondrial microparticles (mtMPs) compromise endothelial integrity, their mechanistic role in endothelial dysfunction and clinical association with malignant cerebral edema (MCE) remain unclear. We analyzed paired intracranial and peripheral arterial blood samples from patients with anterior circulation large vessel occlusion stroke (LVO-AIS) who underwent thrombectomy. Human brain microvascular endothelial cells were stimulated with intracranial versus peripheral mtMPs, followed by RNA sequencing and analysis. The associations between mtMP levels and MCE were evaluated via multivariate logistic regression and receiver operating characteristic (ROC) analyses. Subgroup and sensitivity analyses were conducted to verify the consistency of the findings. Paired samples (n = 16) revealed higher mtMP levels in intracranial blood than in peripheral blood (P = 0.02). RNA sequencing revealed that intracranial mtMPs altered endothelial gene expression (80 upregulated, 52 downregulated), enriching pattern recognition and proinflammatory pathways, alongside enrichment trends in oxidative stress and neutrophil chemotaxis. In the clinical cohort (n = 90, 20% MCE incidence), intracranial mtMPs were elevated in the MCE group (6.9 ± 1.0 vs. 6.1 ± 1.0, P < 0.01) and were identified as an independent risk factor for MCE (adjusted OR, 2.11 [95% CI, 1.11-4.58], P = 0.04). A composite model integrating intracranial mtMPs with key clinical variables demonstrated an AUC of 0.88 (95% CI 0.81-0.96, P < 0.001). Intracranial mtMPs may contribute to endothelial injury and cerebral edema, offering a potential local biomarker for predicting malignant cerebral edema in patients with LVO-AIS. Trial registrationClinicalTrials.gov, NCT04637074. Registered on November 15, 2020.
Indexed as
Identifiers
42479125What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.